METHOD FOR DETERMINING THE SPECIFIC CELLULAR IMMUNE RESPONSE TO CORONAVIRUS ANTIGENS (SARS-CoV-2) Russian patent published in 2022 - IPC G01N33/68 G01N33/569 G01N33/543 G01N33/573 G01N33/531 C12N5/786 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely immunology, and can be used to determine a specific cellular immune response to antigens of the SARS-CoV-2 coronavirus. Isolation of blood mononuclears is carried out, stimulation of isolated blood mononuclears in the wells of polystyrene tablets with SARS-CoV-2 antigens sorbed in them, collection of the supernatant fluid at the end of stimulation and subsequent determination of the concentration of interferon gamma (IFNγ) in the supernatant fluid by enzyme immunoassay (ELISA). Stimulation of isolated blood mononuclears can be carried out by incubating them at 37°C in an atmosphere of 5% CO₂ with the addition of a complete culture medium RPMI-1640 with gentamicin and 10% embryonic calf serum (ECS) to a working concentration in the well of the tablet of 2.5×10⁵ cells. The concentration of IFNγ in the supernatant fluid is defined as the difference between antigen-induced and spontaneous IFNγ production.

EFFECT: method provides the possibility of a simple, effective and convenient assessment of the specific cellular immune response to the antigens of the SARS-CoV-2 coronavirus by determining the specific antigen-stimulated production of IFNγ.

2 cl, 4 tbl